Leflunomide Is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis Remission.

IF 1.1 4区 医学 Q4 ALLERGY Pediatric Allergy Immunology and Pulmonology Pub Date : 2023-06-01 DOI:10.1089/ped.2022.0181
Haiyan Wang, Rongqiong Ou, Bihong Zhang, Sha Li, Yong Liu, Weiping Tan
{"title":"Leflunomide Is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis Remission.","authors":"Haiyan Wang,&nbsp;Rongqiong Ou,&nbsp;Bihong Zhang,&nbsp;Sha Li,&nbsp;Yong Liu,&nbsp;Weiping Tan","doi":"10.1089/ped.2022.0181","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> The present study was aimed to investigate the efficacy of leflunomide in idiopathic pulmonary hemosiderosis (IPH) disease control and glucocorticoid attenuation. <b><i>Methods:</i></b> The efficacy of leflunomide was determined based on disease control, safety, and glucocorticoid attenuation. <b><i>Result:</i></b> A total of 46 children with IPH were included in the present study. Of these 31 patients had been unsuccessfully treated with glucocorticoids before admission at our hospital and did not achieve complete remission; the other 15 patients had not previously received steroids. Leflunomide combined with glucocorticoid was administered to all patients, and all were followed up for a median duration of 3 years. The average hemoglobin level significantly increased and the median minimum steroid dose was significantly decreased after leflunomide administration. <b><i>Conclusion:</i></b> Leflunomide safely and effectively induced and maintained IPH remission and decreased IPH relapse and glucocorticoid dose.</p>","PeriodicalId":54389,"journal":{"name":"Pediatric Allergy Immunology and Pulmonology","volume":"36 2","pages":"62-67"},"PeriodicalIF":1.1000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Allergy Immunology and Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ped.2022.0181","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The present study was aimed to investigate the efficacy of leflunomide in idiopathic pulmonary hemosiderosis (IPH) disease control and glucocorticoid attenuation. Methods: The efficacy of leflunomide was determined based on disease control, safety, and glucocorticoid attenuation. Result: A total of 46 children with IPH were included in the present study. Of these 31 patients had been unsuccessfully treated with glucocorticoids before admission at our hospital and did not achieve complete remission; the other 15 patients had not previously received steroids. Leflunomide combined with glucocorticoid was administered to all patients, and all were followed up for a median duration of 3 years. The average hemoglobin level significantly increased and the median minimum steroid dose was significantly decreased after leflunomide administration. Conclusion: Leflunomide safely and effectively induced and maintained IPH remission and decreased IPH relapse and glucocorticoid dose.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
来氟米特安全有效地诱导和维持特发性肺含铁血黄素病缓解。
目的:探讨来氟米特对特发性肺含铁血黄素病(IPH)的控制和糖皮质激素的抑制作用。方法:从疾病控制、安全性、糖皮质激素衰减等方面评价来氟米特的疗效。结果:本研究共纳入46例IPH患儿。其中31例患者入院前糖皮质激素治疗不成功,未完全缓解;另外15名患者之前没有接受过类固醇治疗。所有患者均给予来氟米特联合糖皮质激素治疗,所有患者均接受中位随访,随访时间为3年。来氟米特给药后平均血红蛋白水平显著升高,类固醇最小中位剂量显著降低。结论:来氟米特安全有效地诱导和维持IPH缓解,减少IPH复发和糖皮质激素剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
23
审稿时长
>12 weeks
期刊介绍: Pediatric Allergy, Immunology, and Pulmonology is a peer-reviewed journal designed to promote understanding and advance the treatment of respiratory, allergic, and immunologic diseases in children. The Journal delivers original translational, clinical, and epidemiologic research on the most common chronic illnesses of children—asthma and allergies—as well as many less common and rare diseases. It emphasizes the developmental implications of the morphological, physiological, pharmacological, and sociological components of these problems, as well as the impact of disease processes on families. Pediatric Allergy, Immunology, and Pulmonology coverage includes: -Functional and genetic immune deficiencies- Interstitial lung diseases- Both common and rare respiratory, allergic, and immunologic diseases- Patient care- Patient education research- Public health policy- International health studies
期刊最新文献
Evolving Trends in Pediatric Allergic Diseases: A Cross-Sectional Study Over 20 Years in the Central Black Sea Region of Turkey. A Cricopharyngeal Bar as an Underrecognized Finding in an Adolescent with Eosinophilic Esophagitis. Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Pediatric Allergy, Immunology, and Pulmonology. Pharmaceutical Therapies for Pediatric Respiratory Disease: Setbacks and Progress in 2024. Asthma and Adolescence: Unique Opportunities for Fostering Asthma Self-Management and Asthma Control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1